Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Multiple Myeloma × WW Domain-Containing Oxidoreductase × Clear all

Phase

Phase 2 2 Phase 1 2 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasm Metastasis 1 Multiple Myeloma 1 Breast Neoplasms 1

Interventions

Dexamethasone 142 Bortezomib 79 Lenalidomide 78 Thalidomide 39 Melphalan 37 daratumumab 36 pomalidomide 32 Cyclophosphamide 29 carfilzomib 23 Calcium Dobesilate 23 Prednisone 18 Doxorubicin 13 elotuzumab 11 Filgrastim 11 ixazomib 10 Peripheral Blood Stem Cell Transplantation 10 isatuximab 9 Vincristine 9 belantamab mafodotin 8 Zoledronic Acid 8 dexamethasone acetate 7 Granulocyte Colony-Stimulating Factor 7 Epoetin Alfa 7 selinexor 5 Carmustine 5 fludarabine 4 Radiotherapy 4 Interferon-alpha 4 Etoposide 4 Denosumab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02412878 2022-09-23

ARROW

Amgen

Phase 3 Completed

478 enrolled 17 charts

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡